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Abstract
Background—Infants aged <1 year are at highest risk for pertussis-related morbidity and 
mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccine 
was recommended for women during each pregnancy to protect infants in the first months of life; 
data on effectiveness of this strategy are currently limited.
Methods—We conducted a case-control evaluation among pertussis cases <2 months old with 
cough onset between January 1, 2011 and December 31, 2014 from six U.S. Emerging Infection 
Program Network states. Controls were hospital-matched and selected by birth certificate. Mothers 
were interviewed to collect information on demographics, household characteristics, and 
healthcare providers. Provider-verified immunization history was obtained on mothers and infants. 
Mothers were considered vaccinated during pregnancy if Tdap was received ≥14 days before 
delivery; trimester was calculated using Tdap date, infant’s date of birth, and gestational age. Odds 
ratios were calculated using multivariable conditional logistic regression; vaccine effectiveness 
(VE) was estimated as (1 – OR) × 100%.
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Results—A total of 240 cases and 535 controls were included; 17 (7.1%) case-mothers and 90 
(16.8%) control-mothers received Tdap during the 3rd trimester of pregnancy. The multivariable 
VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (48.3% – 
90.4%); VE increased to 90.5% (65.2 – 97.4%) against hospitalized cases.
Conclusions—Vaccination during pregnancy is an effective way to protect infants during the 
early months of life. With a continuing resurgence in pertussis, efforts should focus on maximizing 
Tdap uptake among pregnant women.
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BACKGROUND
Despite the dramatic impact of vaccines on the burden of B. pertussis in the United States, 
pertussis remains endemic, and reported cases have increased steadily since the late 1980s. 
In 2012, over 46,000 pertussis cases were reported in the U.S., the largest number since the 
mid-1950s. While causes for the increase are likely multifactorial, waning immunity from 
acellular pertussis vaccination has been documented to be a strong contributor [1].
Infants are at greatest risk for pertussis-related complications and mortality, especially 
during the first months of life [1]. Immunization against pertussis with the 5-dose childhood 
DTaP (diphtheria and tetanus toxoids, and acellular pertussis vaccine) series begins at 2 
months of age, leaving young infants highly susceptible to pertussis. Among case-patients 
<2 months old, approximately 75% are hospitalized and 1 in 100 die [2]. Studies suggest 
that parents and siblings play an important role in transmitting pertussis to vulnerable infants 
[3, 4].
In 2005, two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) 
vaccines were licensed for use as a single booster dose among U.S. adolescents and adults 
[5, 6]. Although the primary goal of Tdap immunization was to provide direct protection to 
the vaccine recipient, recommendations also focused on indirectly protecting infants through 
vaccination of close contacts, a strategy known as “cocooning” [5, 6]. In 2011, the Advisory 
Committee on Immunization Practices (ACIP) recommended vaccinating women with Tdap 
during a single pregnancy as a strategy to protect young infants through the transplacental 
transfer of maternal antibodies [7]. Because maternal antibodies are short-lived and may not 
be sufficient to protect infants of subsequent pregnancies, the recommendation was 
expanded in 2012 to include a dose of Tdap during every pregnancy [8, 9]. Because the 
recommendation for vaccination during pregnancy was made with limited data, post-
implementation evaluations are essential for monitoring effectiveness and longer term 
success of the strategy.
We conducted a multi-state, case-control evaluation to determine the effectiveness of 
maternal Tdap vaccination during pregnancy at preventing pertussis in U.S. infants <2 
months old.
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METHODS
A case of pertussis was defined as the onset of cough illness and at least one of the 
following: laboratory-confirmation (culture or PCR) of pertussis, epidemiological linkage to 
a laboratory-confirmed case, or clinically-compatible illness (cough ≥2 weeks with 
paroxysms, inspiratory whoop or post-tussive vomiting) in an infant <2 months old between 
January 1, 2011 and December 31, 2014. Cases were identified through surveillance in six 
Emerging Infection Program Network sites1[10]. Infants were eligible for enrollment if they 
were at least two days old and resided in the catchment area on their cough onset date, were 
born in a hospital in their state of residence, were ≥37 weeks gestational age at birth, were 
not adopted or in foster care, and did not live in a residential care facility. For each enrolled 
case-infant, we attempted to recruit three control-infants from birth certificates of infants 
born at the same hospital as the case-infant that were <2 months old on the case-infant’s 
cough onset date; once all potential controls meeting these criteria were exhausted, control 
enrollment ended for that case-infant. Eligibility criteria were the same for control-infants as 
for case-infants, and control-infants were additionally considered ineligible if they had a 
pertussis diagnosis prior to the cough onset date of the corresponding case-infant.
Mothers of case and control-infants were interviewed by telephone to collect information on 
demographics, mother and infant healthcare providers, and infant household contacts. The 
reference period for a case-infant and his or her matched controls was defined as the 30-day 
period prior to the case-infant cough onset date. Data used in the comparison of enrolled and 
unenrolled infants with pertussis were obtained from surveillance case report forms, 
maternal interviews, and birth certificate records; surveillance case report form data, which 
included hospitalization status, were collected via patient and physician interview.
Pertussis vaccination status, including brand, manufacturer and lot number, was collected 
through medical providers or state immunization registries for all enrolled case and control-
infants and their mothers. When complete vaccine history was unavailable in registries, all 
medical providers identified during the interview were contacted. Additionally, birth 
hospitals were contacted to obtain case and control maternal Tdap histories. Tdap doses 
were considered valid if received at least two weeks before the case-infant’s cough onset 
date; for control-infants, the date of cough onset for the matched case-infant was used. 
Maternal vaccine history was considered complete when follow-up was exhausted with all 
providers; if there was incomplete follow-up with providers but at least one valid Tdap dose 
was identified, these individuals were included in the analysis. Mothers were considered 
unvaccinated if all medical providers were contacted and did not provide documentation of 
Tdap vaccination and no Tdap records were identified in the immunization registry. When 
more than one Tdap dose was verified, the most recent valid dose was included in the 
analysis. Mothers were classified as vaccinated before pregnancy if Tdap was received at 
1The Emerging Infections Program Network is a collaborative network between CDC and state and local health departments, 
academic institutions, and laboratories that serves as a national resource for surveillance, prevention, and control of emerging 
infectious diseases. This case-control evaluation was conducted statewide in California, Connecticut, Minnesota, and New Mexico, 
and in select counties of New York (Albany, Allegany, Cattaraugus, Chautauqua, Chemung, Clinton, Columbia, Delaware, Erie, Essex, 
Franklin, Fulton, Genesee, Greene, Hamilton, Livingstone, Montgomery, Monroe, Niagara, Ontario, Orleans, Otsego, Rensselaer, 
Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Warren, Washington, Wayne, Wyoming, and Yates) and Oregon 
(Clackamas, Multnomah, and Washington).
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any point prior to pregnancy with the case or control-infant, vaccinated during pregnancy if 
they received Tdap ≥14 days before delivery, and vaccinated post-partum if Tdap was 
received <2 months following the case or control-infant’s birth or in the 14 days before 
delivery; the trimester during which Tdap was administered was calculated from the 
vaccination date, infant’s date of birth, and infant’s gestational age at birth. When available, 
lot numbers were verified with vaccine manufacturers to confirm vaccine type and brand. An 
infant was considered enrolled when the maternal interview, and infant and maternal vaccine 
history were all completed.
Data were analyzed using SAS 9.3. Odds ratios were calculated using multivariable 
conditional logistic regression; vaccine effectiveness (VE) was estimated as (1 – OR) × 
100%. Variables associated (p<0.05) with maternal Tdap vaccination in bivariate analyses 
were included in the multivariable models; those that retained significance in multivariable 
analysis after backwards elimination were included in the final model. Although not 
significant, we retained infant age (weeks) in the final models, because cases and controls 
were not matched on age. Case and control-mothers classified as unvaccinated were used as 
the reference group. Differences between proportions were tested using Pearson’s chi-
squared test or Fisher’s exact test; differences in medians were assessed using the Wilcoxon 
Rank-Sum test.
RESULTS
A total of 788 infants <2 months old with pertussis were identified; of these, 29 (3.7%) were 
born prematurely, 6 (0.76%) were adopted or resided in foster care, 5 (0.63%) were born at a 
hospital outside their state of residence, and 3 (0.38%) were not born in a hospital. Of 745 
infants eligible for enrollment, 251 (33.7%) were enrolled. The remaining 494 (66.3%) were 
not enrolled for the following reasons: 354 (71.7%) had mothers that could not be reached, 
100 (20.2%) did not consent, 31 (6.3%) had incomplete maternal vaccination history follow-
up, 7 (1.4%) did not speak English or Spanish, and 2 (0.4%) had another reason for non-
enrollment. Compared with unenrolled infants with pertussis, mothers of enrolled infants 
were significantly more likely to have post-high school education; no significant differences 
were observed for sex, race, ethnicity, hospitalization, outcome, or insurance type (Table 1).
We identified 5,507 infants eligible to be enrolled as controls, 682 (12.4%) of whom were 
enrolled in the evaluation. The remaining 4,825 were not enrolled for the following reasons: 
4,124 (85.5%) had mothers that could not be reached, 623 (12.9%) did not consent, 53 
(1.1%) had incomplete maternal vaccination history follow-up, 6 (0.1%) resided outside of 
the catchment area on corresponding case-infant cough onset date, 4 (0.1%) did not speak 
English or Spanish, and 15 (0.3%) had another reason for non-enrollment. Demographics of 
enrolled case and control-infants are shown in Table 2. Because there was a disproportionate 
number of enrolled control-infants compared to enrolled case-infants among those <2 weeks 
old, we restricted our analysis to case-infants who were ≥2 weeks old on their cough onset 
date and control-infants who were ≥2 weeks old on their corresponding case-infant’s cough 
onset date (Table 2); 11 (4.4%) case-infants and 147 (21.6%) control-infants were excluded. 
The population for analysis included 240 case-infants and 535 control-infants.
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Overall, 136 (56.7%) case-mothers and 358 (66.9%) control-mothers had at least one valid 
Tdap dose identified. Eighteen (13.2%) of 136 vaccinated case-mothers and 50 (14.0%) of 
358 vaccinated control-mothers had more than one valid dose of Tdap reported (p=0.83); 61 
mothers had two documented doses of Tdap, and 7 had three. Among the 61 women with 
two Tdap doses, the median time between doses was 1,022 days (range: 7 – 2,744 days) and 
did not differ significantly between case and control-mothers (p=0.32).
Figures 1a–1c show the distribution of Tdap doses included in the final model and their 
timing of administration in relation to pregnancy. Of Tdap doses received during pregnancy 
(associated with 22 cases and 117 controls), approximately 77% were received during the 
third trimester, most during the ACIP-recommended 27–36 weeks of gestation (Figure 1a). 
For the 24 case-associated and 67 control-associated doses received before pregnancy, 6 
(25.0%) case-mothers and 46 (68.7%) control-mothers received Tdap ≤2 years before 
pregnancy (Figure 1b). For doses classified as post-partum, 75.9% of control-associated 
doses and 74.4% of case-associated doses were given within the first two days following 
birth; 5 (5.6%) doses among case-mothers and 7 (4.0%) among control-mothers were 
received during the last two weeks of pregnancy and therefore classified as post-partum 
(Figure 1c).
The overall effectiveness of vaccination at any time during the third trimester of pregnancy 
was 77.7% (48.3% – 90.4%; Table 3); the effectiveness of Tdap given during the first or 
second trimester was 64.3% (−13.8% – 88.8%), but confidence bounds overlapped with 
those for the third trimester. When restricting third-trimester doses to the recommended 
window of 27 – 36 weeks, VE was 78.4% (49.8% – 90.7%). There was no effectiveness 
when a dose of Tdap was given to the mother during the postpartum period (4.9%; −49.3% – 
39.5%; Table 3).
Tdap given at any point before pregnancy was 50.8% (2.1% – 75.2%) effective at preventing 
infant pertussis (Table 3). We further stratified this analysis by examining Tdap doses given 
≤2 years before pregnancy and Tdap doses given >2 years before pregnancy; the 
effectiveness of Tdap given >2 years before pregnancy was −25.6% (−207.4 – 48.7%) and 
the effectiveness of Tdap given ≤2 years before pregnancy was 83.0% (49.6% – 94.3%). The 
point estimate for Tdap given ≤2 years before pregnancy was not significantly different than 
the point estimate for Tdap given during the 3rd trimester (p=0.6034).
Approximately 65.4% (157/240) of case-infants were hospitalized during the course of their 
pertussis infection. When we examined the effectiveness of Tdap at preventing infant 
pertussis hospitalizations, the VE point estimate for vaccination during the 3rd trimester 
increased to 90.5% (65.2 – 97.4%). An increase in VE point estimates was also observed for 
doses given at any point before pregnancy, during the 1st or 2nd trimester, and post-partum; 
however, the post-partum estimate remained non-significant (Table 4).
A total of 43/136 (31.6%) vaccinated case-mothers and 102/358 (28.5%) vaccinated control-
mothers received Boostrix™, and 76/136 (55.9%) vaccinated case-mothers and 207/358 
(57.8%) vaccinated control-mothers received Adacel®; brand information was not available 
for the remaining 17/136 (12.5%) case-mothers and 49/358 (13.7%) control-mothers who 
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had record of Tdap receipt. When we calculated the effectiveness of either vaccine product 
at preventing infant disease when administered during the 3rd trimester, point estimates were 
not statistically different from one another (p=0.85).
DISCUSSION
Our findings, using data from multiple U.S. states, add to the growing body of evidence that 
vaccination during pregnancy is effective, underscoring its importance as a key strategy for 
preventing pertussis in young infants. The United Kingdom was first to evaluate Tdap 
vaccination during pregnancy, demonstrating high effectiveness at preventing pertussis 
during the first two months of life [11, 12]. Vaccination during pregnancy was recommended 
in the U.K in late 2012 owing to a sudden increase in pertussis morbidity and mortality 
among infants, and high Tdap coverage (60%) was rapidly achieved among pregnant women 
[11]. Three years post-introduction, high effectiveness has been sustained [13]. Contrary to 
the U.K. experience, U.S. uptake of the recommendation has progressed at a much slower 
pace. A recent survey reports that 48.8% of U.S. pregnant women received Tdap during the 
2015–16 influenza season, an increase of 21.8% from the 2013–14 season [14]. Although 
coverage continues to increase, there is likely considerable variation in vaccine uptake across 
the U.S. and among medical providers caring for pregnant women. Emphasis should be 
placed on maximizing Tdap uptake during pregnancy in order to optimize the benefits of the 
strategy.
Although our results are consistent with those from a U.S. cohort analysis, we found slightly 
lower effectiveness of vaccination during pregnancy than in the U.K., where estimates were 
obtained using similar case-control methodology; a second, more recent U.S. cohort study 
also found higher point estimates of VE, but the CIs were wide and included our estimated 
effectiveness [11, 15, 16]. Ninety percent of infants <1 year old with pertussis reported in 
the U.K. between 2002 and 2009 were hospitalized [17]. In contrast, U.S. data indicate that 
34%–69% of infants with pertussis are hospitalized [3, 6, 18, 19], with the proportion of 
hospitalizations decreasing in recent years [2]. While there could be real differences in the 
epidemiology of severe disease or the threshold for hospitalization of suspect infant cases, 
this disparity more likely reflects differences in case ascertainment practices, and the ability 
of U.S. surveillance to capture more outpatient illness [10]. Interestingly, when our models 
were restricted to hospitalized cases, higher vaccine effectiveness was observed, closely 
mirroring the U.K. estimates. In the U.K. study, all cases were laboratory-confirmed which 
could also lead to a higher VE estimate; however, the majority of our cases were also 
laboratory-confirmed (94%), suggesting that this does not account for our lower estimate.
Sixty-eight percent of our cases were from California (Table 1) which has experienced large 
pertussis epidemics in recent years, with a proportion of cases in Hispanic infants that is 
greater than the proportion of Hispanics in the California birth cohort [20]. As a result, 62% 
of our enrolled cases were Hispanic (Table 1), which is higher than U.S. national estimates 
(49% of pertussis cases aged <2 months with known ethnicity, unpublished data, US 
National Notifiable Disease Surveillance System, 2011–2014). While an increased risk of 
pertussis in Hispanic infants has been reported, additional study is needed to fully 
understand why Hispanic infants are at increased risk [21]. It is reassuring that vaccination 
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during pregnancy is highly effective in a population with a high proportion of Hispanic 
cases, further underscoring the importance of this strategy.
The recommendation for cocooning has been in place since the U.S. introduction of Tdap; 
however, programmatic implementation of the strategy has encountered substantial logistical 
challenges resulting in poor Tdap uptake and incomplete coverage among infant close 
contacts [22, 23]. Consistent with published evaluations of the cocooning strategy, point 
estimates from our analysis, although not reaching significance, show no benefit of a dose of 
Tdap administered to the mother post-partum [16, 24, 25]. Recent data from non-human 
primates has suggested that acellular vaccination, unlike vaccination with whole-cell 
pertussis vaccine, may not preclude B. pertussis colonization and further transmission of the 
organism [26]. In an era of exclusively acellular vaccine use in the U.S., vaccinated 
individuals could remain a significant source of pertussis transmission to young infants, 
highlighting additional shortcomings of cocooning and further underscoring the critical role 
of effective strategies such as vaccination during pregnancy.
Recent studies have brought into question the ideal timing of Tdap administration during 
pregnancy, providing evidence that vaccination during the 2nd or early 3rd trimester may 
maximize transplacental transfer of maternal pertussis antibodies to the infant [27–29]. 
While active transport of maternal antibodies is thought to be minimal before 30 weeks’ 
gestation, vaccination too late in pregnancy could diminish protection provided to the infant 
[30]. Because most Tdap-vaccinated mothers in our evaluation received vaccine during the 
recommended 3rd trimester, our sample size was not adequate to detect a significant 
difference in VE between 3rd trimester doses and doses administered earlier in pregnancy, 
and small numbers left us unable to evaluate narrower time periods. Our analysis did find 
benefit of a dose of Tdap given in the 2 years prior to pregnancy, with a VE point estimate 
not significantly different than that of a dose administered during the 3rd trimester. While we 
were not powered to detect a significant difference between point estimates, this finding is 
consistent with other VE studies that have shown benefit of Tdap prior to pregnancy [16, 
31]. Future studies should not only continue to evaluate the infant immune response to Tdap 
doses administered prior to the third trimester of pregnancy, but also assess how transferred 
antibody correlates with protection against clinical disease.
Although Tdap vaccination during pregnancy is effective at preventing infant pertussis, 
important questions remain. Reduced Tdap effectiveness has been documented among 
adolescents primed with acellular pertussis vaccines compared to cohorts vaccinated with 
whole-cell vaccine [32–34]. Whether the effectiveness of vaccination during or in the two 
years prior to pregnancy will diminish as the number of aP-primed pregnant women 
increases is yet to be determined; the exact timing of Tdap administration could become 
more critical among aP-vaccinated mothers if antibodies diminish more rapidly in these 
women. Maternal immunization during pregnancy also has the potential to blunt an infant’s 
immune response to the DTaP childhood series. While circulating maternal antibodies 
decline rapidly and potential interference is expected to be short-lived, studies have 
generated conflicting evidence on blunting, and its clinical relevance is still largely unknown 
[35–40]. Continued monitoring of the epidemiology of pertussis will be important to detect 
potential shifts in the age distribution of childhood disease.
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Maximizing the protection of young infants remains a high priority, especially in the setting 
of increased pertussis activity. Efforts should focus on the promotion of maternal 
immunization through provider and patient education in order to increase Tdap uptake 
among pregnant women (www.cdc.gov/pertussis/pregnant). Pertussis vaccines with 
improved duration of immunity are needed, but new vaccines remain on the distant horizon. 
While maternal immunization during pregnancy will help bridge the gap until next-
generation pertussis vaccines are licensed and available for use, this highly effective strategy 
will likely remain an integral component of pertussis prevention and control, even in the 
setting of new vaccines.
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Summary of Main Points
Tdap vaccine administered to a mother during the third trimester of pregnancy is 77.7% 
effective at preventing pertussis in infants <2 months of age.
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Figure 1a. Timing of Tdap Doses Classified as During Pregnancy
The white bars represent Tdap doses received by control-associated mothers during 
pregnancy, and the gray bars represent Tdap doses received by case-associated mothers 
during pregnancy.
*2 cases were missing gestational age so the exact week of Tdap administration could not be 
calculated; based on date of birth and Tdap date, both cases were included in the second 
trimester of pregnancy in the analysis models.
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Figure 1b. Timing of Tdap Doses Classified as Before Pregnancy
The white bars represent Tdap doses received by control-associated mothers before 
pregnancy, and the gray bars represent Tdap doses received by case-associated mothers 
before pregnancy.
*1 case missing gestational age so the exact month of Tdap administration before pregnancy 
could not be calculated; based on date of birth and Tdap date, this case was included in the 
≤2 year group in the analysis models.
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Figure 1c. Timing of Tdap Doses Classified as Post-partum
The white bars represent Tdap doses received by control-associated mothers during the post-
partum period, and the gray bars represent Tdap doses received by case-associated mothers 
during the post-partum period.
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Table 1
Characteristics of Enrolled and Non-enrolled Infants with Pertussis
Enrolled (%) n=251 Non-enrolled (%) n=537 p-value
Sexa, male 123 (49.0) 258 (49.3) .99
Raceb .07
 White 199 (80.9) 356 (77.5)
 Black 22 (8.9) 30 (6.5)
 Other 25 (10.1) 73 (15.9)
Hispanic Ethnicityc 156 (62.2) 297 (60.0) .57
Hospitalizedd 164 (66.1) 305 (67.6) .69
Died 0 7 (1.3) —
State .0001
 California 172 (68.5) 418 (77.8)
 Connecticut 14 (5.6) 9 (1.7)
 Minnesota 19 (7.6) 30 (5.6)
 New Mexico 22 (8.7) 17 (3.2)
 New York 12 (4.8) 42 (7.8)
 Oregon 12 (4.8) 21 (3.9)
Case Classificatione 0.31
 Laboratory-confirmed 235 (93.6) 492 (91.6)
 Epidemiologically-linked 1 (0.4) 9 (1.7)
Clinically-compatible 15 (6.0) 35 (6.5)
Insurance Typef .05
 Medicaid or no insurance 131 (59.8) 299 (67.5)
 Private, self-pay, or other 88 (40.2) 144 (32.5)
Maternal Educationg .001
 High School or less 120 (53.6) 295 (66.6)
 More than High School 104 (46.4) 148 (33.4)
aCalculated from those with known sex (n=251 for enrolled; n=523 for non-enrolled)
bCalculated from those with known race (n=246 for enrolled; n=459 for non-enrolled)
cCalculated from those with known ethnicity (n=495 non-enrolled)
dCalculated from those with known hospitalization status (n=248 enrolled; n=451 non-enrolled)
eCalculated from those with known case classification (n=251 enrolled; n=536 non-enrolled)
fCalculated from those with known insurance type (n=219 enrolled; n=443 non-enrolled)
gCalculated from those with known maternal education (n=224 enrolled; n=443 non-enrolled)
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Table 2
Demographics of Enrolled Infants, by Case Status
Cases (%) n=251 Controls (%) n=682 p-value
Sex, male 123 (49.0) 330 (48.4) .87
Racea
 White 199 (80.9) 543 (81.9) .62
 Black 22 (8.9) 47 (7.1)
 Other 25 (10.2) 73 (11.0)
Hispanic Ethnicity 156 (62.2) 344 (50.4) .002
Age in weeksb
 0–1 weeks 11 (4.4) 147 (21.6) <.0001
 2–3 weeks 66 (26.3) 147 (21.6)
 4–5 weeks 70 (27.9) 153 (22.4)
 6–7 weeks 79 (31.5) 178 (26.1)
 8 weeks 25 (9.9) 57 (8.3)
Infants with a DTaP dose 2 (0.8) 3 (0.4) .62
aCalculated from those with known race (n=246 for case-infants; n=663 for control-infants)
bAge at date of cough onset (for case-infants) or date of cough onset of matched case-infant (for control-infants)
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